Pacira BioSciences Management

Mr. Frank D. Lee serves as Chief Executive Officer & Director at Pacira BioSciences, Inc. since January 02, 2024. He is the Executive Chairperson of the Board at Therini Bio, Inc. from May 2023. He has glo...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Charles Reinhart	Chief Financial Officer	7.9yrs	US$1.75m	0.046% $ 548.6k
Daryl Gaugler	Chief Operating Officer	1.9yrs	US$2.29m	0.015% $ 181.5k
Kristen Williams	Chief Administrative Officer & Secretary	9.5yrs	US$1.77m	0% $ 0
Anthony Molloy	Chief Legal & Compliance Officer	2.3yrs	US$2.05m	0.028% $ 328.4k
David Stack	Advisor	less than a year	US$6.85m	0.51% $ 6.0m
Frank Lee	CEO & Director	less than a year	no data	no data
Lauren Riker	Principal Accounting Officer & Senior VP of Finance	12.1yrs	US$288.82k	0.010% $ 118.3k
Susan Mesco	Head of Investor Relations	no data	no data	no data
Richard Kahr	Vice President of Human Resources	8.8yrs	no data	no data
Jonathan Slonin	Chief Medical Officer	2.8yrs	US$2.12m	0.0048% $ 57.2k
Christopher Young	Chief Manufacturing Officer	less than a year	no data	no data

2.5yrs

Average Tenure

51yo

Average Age

Experienced Management: PCRX's management team is considered experienced (2.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Frank Lee	CEO & Director	less than a year	no data	no data
Laura Brege	Independent Director	12.8yrs	US$362.57k	0.021% $ 243.4k
Paul Hastings	Chairman of the Board	12.8yrs	US$383.57k	0.014% $ 168.2k
Gary Pace	Independent Director	15.8yrs	US$340.07k	0.044% $ 519.0k
Andreas Wicki	Independent Director	17.3yrs	no data	no data
Mark Kronenfeld	Independent Director	10.8yrs	US$360.33k	0.038% $ 456.4k
Christopher Christie	Independent Director	4.6yrs	US$325.07k	0.0075% $ 88.9k
Alethia Young	Independent Director	less than a year	no data	no data
Marcelo Bigal	Independent Director	less than a year	no data	no data
Abraham Ceesay	Independent Director	less than a year	no data	no data
Mark Froimson	Independent Director	6.8yrs	US$346.07k	0.013% $ 154.7k
Michael Yang	Independent Director	less than a year	no data	no data

5.7yrs

Average Tenure

62yo

Average Age

Experienced Board: PCRX's board of directors are considered experienced (5.7 years average tenure).

Pacira BioSciences Management

Management criteria checks 2/4

Key information

Recent management updates

Pacira BioSciences, Inc., Annual General Meeting, Jun 11, 2024

Independent Director recently sold US$3.7m worth of stock

Independent Director notifies of intention to sell stock

Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024

High number of new directors

Pacira BioSciences, Inc. Appoints Frank D. Lee as Chief Executive Officer, Effective January 2, 2024

Recent updates

Pacira BioSciences, Inc., Annual General Meeting, Jun 11, 2024

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

Independent Director recently sold US$3.7m worth of stock

Independent Director notifies of intention to sell stock

Consensus EPS estimates fall by 21%

Full year 2023 earnings: EPS exceeds analyst expectations

Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024

Pacira BioSciences, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Pacira BioSciences, Inc. Announces Publication of Pivotal Study of Exparel as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?

High number of new directors

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement

Pacira BioSciences, Inc. Appoints Frank D. Lee as Chief Executive Officer, Effective January 2, 2024

Insider notifies of intention to sell stock

Pacira BioSciences, Inc. Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Third quarter 2023 earnings released: EPS: US$0.23 (vs US$0.015 loss in 3Q 2022)

Pacira BioSciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Pacira Biosciences Appoints Four New Independent Directors to Its Board of Directors

Pacira BioSciences, Inc. Announces Retirement of David Stack to Retire as Its CEO

Price target decreased by 9.5% to US$55.89

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?

Pacira BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Chief Financial Officer recently sold US$915k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Pacira BioSciences, Inc. Provides Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings: EPS misses analyst expectations

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

Independent Director notifies of intention to sell stock

Full year 2022 earnings: EPS misses analyst expectations

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.40 profit in 3Q 2021)

Pacira BioSciences, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Assessing Pacira BioSciences' Growth Prospects

President of Rest of World notifies of intention to sell stock

Insufficient new directors

Pacira BioSciences guides Q3 revenue below consensus

Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures

Pacira Biosciences Announces Positive Topline Data from Phase 3 Study of Exparel as A Single-Dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy

Pacira BioSciences, Inc. Receives Positive CHMP Opinion for Exparel® for the Treatment of Postsurgical Pain in Children Aged 6 or Older

EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids

Pacira BioSciences records 17.7% sequential growth in August revenue

Pacira Biosciences, Inc. Announces Positive Topline Data from Phase 3 Study of EXPAREL as A Single-Dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty

Pacira BioSciences provides update on July product sales

Pacira BioSciences Q2 2022 Earnings Preview

Pacira BioSciences, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Pacira Biosciences, Inc. Not to Provide Revenue Guidance for the Fiscal Year 2022

Pacira BioSciences sees Q2 revenue below consensus

Chief Clinical Officer recently sold US$53k worth of stock

Chief Technical Officer exercised options to buy US$322k worth of stock.

Investor sentiment deteriorated over the past week

Chairman & CEO recently sold US$734k worth of stock

Chief Clinical Officer exercised options to buy US$129k worth of stock.

Independent Director recently sold US$59k worth of stock

Consensus EPS estimates fall by 28%

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chairman & CEO exercised options to buy US$1.5m worth of stock.

President of Rest of World exercised options and sold US$861k worth of stock

Insufficient new directors

Pacira BioSciences, Inc., Annual General Meeting, Jun 07, 2022

President of Rest of World exercised options and sold US$861k worth of stock

Pacira BioSciences, Inc. Provides Preliminary Revenue Guidance for the First Quarter of 2022